AiCuris Anti-infective Cures AG

https://www.aicuris.com

AiCuris, a clinical-stage biopharmaceutical company, was founded in 2006 as a spin-off from Bayer and focuses on the discovery and development of drugs targeting infectious diseases. PREVYMIS™ (letermovir), a first-in-class non-nucleoside cytomegalovirus (CMV) inhibitor acting via a novel mechanism of action, was licensed to MSD in 2012 and is approved in the EU, US, Japan and other parts of the world for the prevention of human CMV infections in adults who received allogeneic hematopoietic stem cell transplantation. The Company has a broad pipeline of clinical-stage and pre-clinical anti-viral and anti-bacterial product candidates. Its wholly owned lead asset, pritelivir, targeting single- or double-resistant herpes simplex virus (HSV) infections, is in phase 3 clinical development. Additional candidates are in development for the treatment of viruses, such as hepatitis B virus (HBV), adenoviruses and BK virus (BKV), as well as SARS-CoV2 and other viruses with pandemic potential. In the field of antibacterials, AiCuris seeks to develop innovative treatment options for indications with high medical need, including life-threatening, multidrug-resistant, hospital-treated pathogens. Product candidates for antimicrobioal resistance (AMR), diabetic foot ulcers and sepsis are in pre-clinical development. AiCuris is supported by a strong shareholder base, including lead investor SANTO Holding. *

	Start	2021-05-25 reorganised before
	Group	STRÜNGMANN Group (family Strüngmann)
	Predecessor	AiCuris Anti-infective Cures GmbH
	Industry	anti-infective drug
	Industry 2	Prevymis™
	Person	Zimmermann, Holger (AiCuris 202304– Chief Research + Development Officer before CEO before CSO)
	Person 2	Schmoll, Holger (AiCuris –2010–202212 CFO LEFT 12/22)

	Region	Wuppertal
	Country	Germany
	Street	475 Friedrich-Ebert-Str. Geb. 302
	City	42117 Wuppertal
		Address record changed: 2022-09-17

Basic data	Employees	C: 51 to 100 (2012-10-06)

		* Document for »About Section«: AiCuris Anti-infective Cures AG. (9/1/22). "Press Release: AiCuris Appoints Experienced Business Leader Dr. Sabrina Kuttruff-Coqui as Chief Financial Officer". Wuppertal.

		Record changed: 2025-03-16

Picture Informa Connect BioProcess Intl Europe 2025 Hamburg Register 650x200px

More documents for STRÜNGMANN Group (family Strüngmann)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)